Replimmune ramps up layoffs to cover 60% of workforce amid ongoing fallout of FDA rejection

Summary: Replimune, a medical company in Massachusetts, is letting go of 60% of its workers. This huge cut comes after the FDA said "no" to their new skin cancer drug, RP1, for a second time. The FDA stated there wasn't enough proof from the company's tests to show that the drug worked well.

However, Replimune's CEO, Sushil Patel, strongly disagreed. He blamed the FDA's slow and confusing rules, saying the system failed the patients, not the medicine. Even with the massive layoffs, the company isn't giving up. They will stay open and keep working on another cancer drug called RP2.

For more details, see rssapp-fiercepharma-com at fiercebiotech.com/biotech/replimune-sheds-60-staff-after-fda-rejection-vows-continue-operations (opens in new tab)